Targeting alfa 1beta1 integrin in cancer development
靶向阿尔法 1β1 整合素在癌症发展中的作用
基本信息
- 批准号:7217856
- 负责人:
- 金额:$ 22.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-04-01 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAdhesionsAlanineAmino AcidsAntibodiesApoptosisArginineAutomobile DrivingBasement membraneBindingBinding SitesBiological AssayBiological ModelsBloodBlood CirculationBlood VesselsBlood capillariesC57BL/6 MouseCell AdhesionCell LineCell ProliferationCell Proliferation RegulationCellsChemicalsChickensChinese Hamster Ovary CellCollagenCollagen ReceptorsCollagen Type ICollagen Type IVCoturnix japonicaCountDataData ReportingDermalDetectionDevelopmentDisintegrinsDisulfidesEffectivenessEndothelial CellsEnzyme-Linked Immunosorbent AssayEvaluationFamilyFibroblast Growth Factor 2Flow CytometryGelGrowthGrowth FactorHumanHybridsImmigrationIn VitroIntegrin BindingIntegrinsInvestigationLeadLeucineLewis Lung CarcinomaLigandsLocalizedLungMAP Kinase GeneMAP Kinase ModulesMalignant NeoplasmsMalignant neoplasm of lungMediator of activation proteinMelanoma CellMethodsMigration AssayMitogen-Activated Protein KinasesModelingMolecularMonoclonal AntibodiesMovementMusMutationNeoplasm MetastasisNude MiceNumbersOne-Step dentin bonding systemOrganOxalic AcidOxalic AcidsPathway interactionsPatternPlayProcessPublishingRadialRecombinantsReportingResearchResearch PersonnelRoleSeriesSignal Transduction PathwaySite-Directed MutagenesisSkinSolid NeoplasmStagingStaining methodStainsStreamSystemTechnologyTestingTissuesTubeVascular Endothelial Growth FactorsWestern BlottingWorkXenograft procedureanalogangiogenesisannexin A5anticancer researchbasecancer cellcancer therapycapillarycaspase-3cell motilitycrosslinkechistatineggin vitro Assayin vitro Modelin vivoin vivo Modelinhibitor/antagonistintegrin alpha1beta1interstitialmatrigelmelanomamigrationmodel designmolecular massmouse modelneovascularizationreceptorresearch studysynthetic proteintumortumor growthtumor progression
项目摘要
DESCRIPTION (provided by applicant): The growing of solid tumors highly depends on angiogenesis. In this new vessel formation process the integrins, expressed on endothelial cells are important mediators. Inhibition of function of these integrins is currently one of the directions in cancer research. Moreover, integrins expressed on cancer cells are involved in migration of these cells during metastasis. In the proposed research plan, we will investigate ct 1131 integrin (VLA-1), which is recognized as a specific collagen IV receptor. We will focus our research on two inhibitors of VLA-1, obtustatin and viperisrastatin. Both of them belong to disintegrin family, and are low molecular mass inhibitors (4.2 kDa) of VLA-1. The activity of these disintegrins has been localized within their integrin-binding loop as an active sequence KTS. Obtustatin showed potent angiostatic activity in the chicken CAM model in vivo, and in tube EC formation assay in vitro. Moreover, obtustatin inhibited Lewis lung cancer development in syngeneic mouse model. The activity of KTS-disintegrins will be further tested on growing tumor induced by mouse melanoma B 16 and M-3 cell lines in the syngeneic mouse, and human melanoma cell lines, MV3, HS.939T, A-375, C32, and A2058 in nude mice. The participation VLA-1 in metastasis of these cell lines to the lung will be investigated in vivo using syngeneic and nude mice. To explain the mechanism of the angiostatic effect of KTS containing disintegrins, series of experiments will be performed to investigate their effect on microvascular EC. The preliminary data showed that obtustatin induced apoptosis in these cells and inhibited their proliferation. Based on the previous reports indicating involvement of VLA-1 in signal transduction pathway dependent on MAPK, the effect of KTS-disintegrins on activation of this pathway will be evaluated. Moreover, radial migration assay in collagen gel will be proposed. That in vitro assay imitates movement of EC during early stage of neovascularization after dissolution of the basement membrane. The effect of both disintegrins in EC motility in this model will be tested. Obtustatin and its naturally occurring analog viperisrastatin may be models for designing of synthetic or recombinant compounds, which may be useful in cancer therapy. In summary, the work with KTS containing disintegrins may lead to the better understanding of the involvement of VLA-1 in cancer progression and metastasis, as well as contribute to an understanding of the role of VLA-1 in angiogenesis.
描述(申请人提供):实体肿瘤的生长高度依赖血管生成。在这个新的血管形成过程中,表达在内皮细胞上的整合素是重要的介质。抑制这些整合素的功能是目前癌症研究的方向之一。此外,癌细胞上表达的整合素参与了癌细胞在转移过程中的迁移。在拟议的研究计划中,我们将研究ct1131整合素(VLA-1),它被认为是一种特异性的IV型胶原受体。我们将重点研究VLA-1的两种抑制剂--奥布他丁和蛇毒抑素。它们都属于去整合素家族,都是VLA-1的低分子量抑制剂(4.2 kDa)。这些去整合素的活性被定位在它们的整合素结合环中,作为活性序列KTS。在体内的鸡CAM模型和体外的试管内皮细胞形成实验中,Obtustatin显示了很强的血管抑制活性。此外,奥布他丁还能抑制同基因小鼠模型Lewis肺癌的发生。KTS去整合素的活性将进一步在小鼠黑色素瘤B16和M-3细胞系在同基因小鼠体内以及人黑色素瘤细胞系MV3、HS.939T、A-375、C32和A2058裸鼠体内诱导生长的肿瘤上进行检测。VLA-1参与这些细胞系向肺转移的作用将在体内使用同基因小鼠和裸鼠进行研究。为了解释含有去整合素的KTS的血管抑制作用的机制,我们将通过一系列的实验来研究它们对微血管内皮细胞的影响。初步数据显示,奥布他丁可诱导这些细胞发生凋亡,并抑制其增殖。根据已有报道表明VLA-1参与MAPK依赖的信号转导通路,我们将评估KTS-disIntegrins对该通路激活的影响。此外,还将提出在胶原凝胶中的径向迁移分析。体外实验模拟基底膜溶解后新生血管早期内皮细胞的运动。这两种去整合素在该模型中对EC运动的影响将被测试。Obtustatin及其天然类似物Viperisrastatin可能是设计合成或重组化合物的模型,这可能在癌症治疗中有用。总之,使用含有去整合素的KTS的工作可能有助于更好地理解VLA-1在肿瘤进展和转移中的作用,以及有助于理解VLA-1在血管生成中的作用。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Functional characteristic of snake venom disintegrins: potential therapeutic implication.
- DOI:10.2174/1381612053381765
- 发表时间:2005-02
- 期刊:
- 影响因子:3.1
- 作者:C. Marcinkiewicz
- 通讯作者:C. Marcinkiewicz
Effect of VP12 and viperistatin on inhibition of collagen-receptor-dependent melanoma metastasis.
VP12 和 viperistatin 对抑制胶原受体依赖性黑色素瘤转移的作用。
- DOI:10.4161/cbt.8.15.8999
- 发表时间:2009
- 期刊:
- 影响因子:3.6
- 作者:Staniszewska,Izabela;Walsh,ErinM;Rothman,VickiL;Gaathon,Ariel;Tuszynski,GeorgeP;Calvete,JuanJ;Lazarovici,Philip;Marcinkiewicz,Cezary
- 通讯作者:Marcinkiewicz,Cezary
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CEZARY MARCINKIEWICZ其他文献
CEZARY MARCINKIEWICZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CEZARY MARCINKIEWICZ', 18)}}的其他基金
Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis
血小板反应蛋白-1 与 α9β1 整合素在胶质瘤血管生成中的相互作用
- 批准号:
8193132 - 财政年份:2009
- 资助金额:
$ 22.96万 - 项目类别:
Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis
血小板反应蛋白-1 与 α9β1 整合素在胶质瘤血管生成中的相互作用
- 批准号:
7730264 - 财政年份:2009
- 资助金额:
$ 22.96万 - 项目类别:
Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis
血小板反应蛋白-1 与 α9β1 整合素在胶质瘤血管生成中的相互作用
- 批准号:
8288605 - 财政年份:2009
- 资助金额:
$ 22.96万 - 项目类别:
Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis
血小板反应蛋白-1 与 α9β1 整合素在胶质瘤血管生成中的相互作用
- 批准号:
7894790 - 财政年份:2009
- 资助金额:
$ 22.96万 - 项目类别:
Targeting alfa 1beta1 integrin in cancer development
靶向阿尔法 1β1 整合素在癌症发展中的作用
- 批准号:
6862778 - 财政年份:2004
- 资助金额:
$ 22.96万 - 项目类别:
Targeting alfa 1beta1 integrin in cancer development
靶向阿尔法 1β1 整合素在癌症发展中的作用
- 批准号:
7048567 - 财政年份:2004
- 资助金额:
$ 22.96万 - 项目类别:
Targeting alfa 1beta1 integrin in cancer development
靶向阿尔法 1β1 整合素在癌症发展中的作用
- 批准号:
6726626 - 财政年份:2004
- 资助金额:
$ 22.96万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 22.96万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 22.96万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 22.96万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 22.96万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 22.96万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 22.96万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 22.96万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 22.96万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 22.96万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 22.96万 - 项目类别:














{{item.name}}会员




